Cancers Selected for Study
Following the success of The Cancer Genome Atlas (TCGA) Pilot Project, NIH announced in September 2009 that it is investing $275 million in TCGA over the next two years of this five-year program to chart the genomic changes involved in more than 20 types of cancer. To date, TCGA has achieved comprehensive sequencing, characterization, and analysis of the genomic changes in the brain cancer, glioblastoma multiforme, and ovarian cancer.
Cancers selected for study were chosen based on specific criteria that include:
- Poor prognosis and overall public health impact
- Availability of human tumor and matched-normal tissue samples that meet TCGA standards for patient consent, quality and quantity
Below is a list of cancers that have been selected for study based on the criteria outlined above. The TCGA program has collected the necessary quality and quantity of samples for these cancers to move them into the TCGA project pipeline. Scheduling for sequencing and characterization for these cancers will be dependent on the capacity of the project pipeline. To view TCGA's clinical data forms, please visit the Biospecimen Core Resource's website.
Please note that the list of cancers below is not a comprehensive list and TCGA is actively seeking samples for additional cancer types. This list is subject to change based on the flow of tissues to the project pipeline.
TCGA leadership will continue to keep the cancer community apprised of changes to this list.